Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of microglial cell activation. [GO_REF:0000058, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:19100238]
Microglial cell activation is a complex process tightly regulated by a delicate balance of pro- and anti-inflammatory signals. These cells, the resident immune cells of the central nervous system (CNS), play a crucial role in maintaining brain homeostasis and responding to various insults such as injury, infection, and neurodegeneration. The activation process is characterized by a series of morphological and functional changes, ultimately leading to the release of various mediators that influence the surrounding environment.
The initial trigger for microglial activation can be diverse, including pathogen-associated molecular patterns (PAMPs) released from invading pathogens, damage-associated molecular patterns (DAMPs) released from injured cells, and various cytokines and chemokines produced by other CNS cells. These stimuli activate pattern recognition receptors (PRRs) expressed on the microglial cell surface, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (RLRs).
Upon PRR activation, downstream signaling cascades are triggered, leading to the production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and chemokines, such as CCL2 and CXCL10. These molecules recruit other immune cells to the site of injury and promote inflammation.
Alongside the pro-inflammatory response, microglia also engage in anti-inflammatory mechanisms to limit the extent of inflammation and promote tissue repair. This involves the release of anti-inflammatory cytokines, such as IL-10 and TGF-β, and the expression of phagocytic receptors that remove cellular debris and pathogens.
The regulation of microglial activation is highly dependent on the specific stimuli and the microenvironment. For instance, chronic activation of microglia can contribute to neurotoxicity and exacerbate neurodegenerative diseases. Conversely, precise regulation of microglial activity is essential for effective immune defense and tissue repair.
Several factors contribute to the fine-tuning of microglial activation, including:
* **Cytokine and chemokine signaling:** The interplay of various pro- and anti-inflammatory cytokines and chemokines modulates the activation state of microglia.
* **Neurotransmitter signaling:** Neurotransmitters like glutamate and GABA can directly influence microglial activation and function.
* **Microglial-neuron interactions:** Microglia can sense neuronal distress and activate specific signaling pathways to promote neuronal survival or initiate phagocytosis.
* **Extracellular matrix components:** The composition of the extracellular matrix can influence microglial morphology, migration, and activation.
* **Epigenetic regulation:** Alterations in gene expression patterns through epigenetic mechanisms contribute to the long-term effects of microglial activation.
Understanding the intricate mechanisms governing microglial activation is essential for developing therapeutic strategies for various CNS disorders. Targeting specific signaling pathways or modulating the microenvironment can potentially reprogram microglial function and promote neuroprotection.'
```"
Protein | Definition | Taxonomy |
---|---|---|
Sphingosine kinase 1 | A sphingosine kinase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9NYA1] | Homo sapiens (human) |
Serine-protein kinase ATM | A serine-protein kinase ATM that is encoded in the genome of human. [PRO:CNA] | Homo sapiens (human) |
Interleukin-6 | An interleukin-6 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P05231] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
pd 173074 | aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist | |
caffeine | purine alkaloid; trimethylxanthine | adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic | |
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source | chromones; morpholines; organochlorine compound | autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector |
bergenin | bergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structure | trihydroxybenzoic acid | metabolite |
fingolimod hydrochloride | fingolimod hydrochloride : The hydrochloride salt of 2-amino-2-[2-(4-octylphenyl) ethyl]-1,3-propanediol (fingolimod). Fingolimod Hydrochloride: A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS. | hydrochloride | immunosuppressive agent; prodrug; sphingosine-1-phosphate receptor agonist |
schizandrin b | schizandrin B: a phytogenic antineoplastic agent with anti-inflammatory activity; isolated from Schisandra plant | ||
4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol | substituted aniline | ||
thiourea | thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur. Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS. | one-carbon compound; thioureas; ureas | antioxidant; chromophore |
safingol | safingol: RN given refers to the (R-(R*,S*))-isomer | amino alcohol | |
ku 55933 | 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one: specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; structure in first source | ||
sphingosine | 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4. sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds. | sphing-4-enine | human metabolite; mouse metabolite |
n,n-dimethylsphingenine | N,N-dimethylsphingosine : A sphingoid that is sphingosine in which the two amino hydrogens are replaced by methyl groups. N,N-dimethylsphingosine: a sphingosine kinase inhibitor | aminodiol; sphingoid; tertiary amino compound | EC 2.7.1.91 (sphingosine kinase) inhibitor; metabolite |
cgk 733 | diarylmethane | ||
nu 7026 | 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source | organic heterotricyclic compound; organooxygen compound | |
es-285 | 1-deoxysphinganine : A bioactive sphingoid, sphinganine, in which the terminal hydroxy group has been replaced by a hydrogen. spisulosine: from marine organism, Spisula polynyma; structure in first source | amino alcohol; sphingoid | antineoplastic agent |
nu 7441 | 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one: structure in first source | dibenzothiophenes | |
ku-0060648 | dibenzothiophenes | ||
dactolisib | dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment. dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR | imidazoquinoline; nitrile; quinolines; ring assembly; ureas | antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor |
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide | organochlorine compound | ||
ku 60019 | |||
bi 653048 bs h3po4 | BI 653048 BS H3PO4: structure in first source | ||
cp 466722 | quinazolines | ||
bml 258 | |||
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine | indoles | ||
ve 821 | 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide: an antineoplastic agent; structure in first source | aromatic amide | |
torin 2 | torin 2 : A member of the class of pyridoquinolines that is benzo[h][1,6]naphthyridin-2-one carrying additional 3-(trifluoromethyl)phenyl and 6-aminopyridin-3-yl substituents at positions 1 and 9 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties. | aminopyridine; organofluorine compound; primary amino compound; pyridoquinoline | antineoplastic agent; mTOR inhibitor |
byl719 | proline derivative | ||
cc-115 | 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one: an mTOR kinase inhibitor; structure in first source | ||
vx-970 | berzosertib: an ATR kinase inhibitor | sulfonamide | |
pf-543 | PF-543: Sphingosine Kinase 1 Selective Inhibitor; structure in first source | sulfonamide | |
rome | (2R)-2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol : A 2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol that has R-configuration. It is a sphingosine kinase-2 inhibitor. Rome: The capital city of Italy. | 2-amino-2-(methoxymethyl)-4-(4-octylphenyl)butan-1-ol | EC 2.7.1.91 (sphingosine kinase) inhibitor |
etp-46464 | ETP-46464: inhibits ATM and Rad3-related kinase; structure in first source |